Vitiligo From Checkpoint Inhibitors Not Limited to Melanoma

The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed.

Vitiligo induced by immune checkpoint inhibitors (ICIs) can occur in virtually any type of cancer.

The finding challenges the notion that ICI-induced vitiligo is limited to melanoma patients.
With growing use of checkpoint inhibitors for nonmelanoma cancers, the diversity of patients’ skin color is expected to increase, leading to a greater impact of vitiligo on quality of life and importance of vitiligo-related outcomes.